Ann Rheum Dis:非甾体抗炎药与 COVID-19 死亡风险

2021-06-21 xiangting MedSci原创

这项研究没有发现常规使用 NSAID 对 COVID-19 相关死亡有有害影响。COVID-19不影响NSAID 的常规使用。

研究表明风湿病患者使用的特定药物与COVID-19死亡率的升高或降低相关。这项研究分析了非甾体抗炎药 (NSAIDs) COVID-19 死亡之间的相关性。

                                     

 研究人员于 2020 3 1 日至 6 14 日进行了两项队列研究。代表英国国家卫生服务中心使用了英国的常规临床数据与死亡数据。研究 1 从一般人群中确定了过去 3 年使用 NSAID的患者。研究 2 确定了类风湿性关节炎/骨关节炎患者。暴露被定义为 2020 3 1 日之前的 4 个月内使用过非甾体抗炎药。使用 Cox 回归估算与目前不使用非甾体抗炎药相比,目前使用非甾体抗炎药患者COVID-19 相关死亡的 HRs,并考虑了年龄、性别、合并症、其他药物和地理区域等因素。

 

结果如下:研究 1 ,在一般人群中纳入 536 423 名目前使用 NSAID 的患者和 1 927 284 名不使用 NSAID 的人。在多因素调整模型中,没有观察到与目前使用NSAID相关的 COVID-19死亡率差异(HR 0.9695% CI 0.80-1.14)。研究 2 纳入1 708 781 名类风湿性关节炎/骨关节炎患者,其中175 495 名患者(10%)目前使用 NSAID。在多因素调整模型中,观察到与不使用 NSAID相比,目前使用 NSAID的 COVID-19 相关死亡风险较低(HR 0.78,95% CI 0.64-0.94)。

                        图:风湿性关节炎/骨关节炎患者目前使用NSAID的COVID-19死亡风险

由此可见,这项研究没有发现常规使用 NSAID 对 COVID-19 相关死亡有有害影响。COVID-19不影响NSAID 的常规使用。

 

原始出处:

Angel YS Wong. Use of non-steroidal anti-inflammatory drugs and risk of death from COVID-19: an OpenSAFELY cohort analysis based on two cohorts. Ann Rheum Dis. July 2021.

 

 

 

 

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2013639, encodeId=f5be201363946, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Wed Mar 30 05:01:38 CST 2022, time=2022-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001358, encodeId=86471001358ba, content=是否全炎症通路的控制,比单炎症通道的控制,对新冠肺有更好的治疗效果的?, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7ced1734358, createdName=1def5843m65(暂无匿称), createdTime=Wed Jul 21 10:54:17 CST 2021, time=2021-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256094, encodeId=06ec125609446, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Wed Jun 23 02:01:38 CST 2021, time=2021-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1338708, encodeId=d66e1338e08d9, content=<a href='/topic/show?id=afff99560c4' target=_blank style='color:#2F92EE;'>#非甾体抗炎药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99560, encryptionId=afff99560c4, topicName=非甾体抗炎药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/7F67E3BE360D6DD1D0A62E3E71E23CB6/100, createdBy=9d8a2500148, createdName=ms8888626721583891, createdTime=Wed Jun 23 02:01:38 CST 2021, time=2021-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1346785, encodeId=dd071346e85d5, content=<a href='/topic/show?id=f20155404fc' target=_blank style='color:#2F92EE;'>#抗炎药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55404, encryptionId=f20155404fc, topicName=抗炎药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Wed Jun 23 02:01:38 CST 2021, time=2021-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=975392, encodeId=ab949e53927b, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=368f5530121, createdName=ms1000000640559067, createdTime=Mon Jun 21 11:18:55 CST 2021, time=2021-06-21, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2013639, encodeId=f5be201363946, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Wed Mar 30 05:01:38 CST 2022, time=2022-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001358, encodeId=86471001358ba, content=是否全炎症通路的控制,比单炎症通道的控制,对新冠肺有更好的治疗效果的?, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7ced1734358, createdName=1def5843m65(暂无匿称), createdTime=Wed Jul 21 10:54:17 CST 2021, time=2021-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256094, encodeId=06ec125609446, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Wed Jun 23 02:01:38 CST 2021, time=2021-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1338708, encodeId=d66e1338e08d9, content=<a href='/topic/show?id=afff99560c4' target=_blank style='color:#2F92EE;'>#非甾体抗炎药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99560, encryptionId=afff99560c4, topicName=非甾体抗炎药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/7F67E3BE360D6DD1D0A62E3E71E23CB6/100, createdBy=9d8a2500148, createdName=ms8888626721583891, createdTime=Wed Jun 23 02:01:38 CST 2021, time=2021-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1346785, encodeId=dd071346e85d5, content=<a href='/topic/show?id=f20155404fc' target=_blank style='color:#2F92EE;'>#抗炎药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55404, encryptionId=f20155404fc, topicName=抗炎药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Wed Jun 23 02:01:38 CST 2021, time=2021-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=975392, encodeId=ab949e53927b, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=368f5530121, createdName=ms1000000640559067, createdTime=Mon Jun 21 11:18:55 CST 2021, time=2021-06-21, status=1, ipAttribution=)]
    2021-07-21 1def5843m65(暂无匿称)

    是否全炎症通路的控制,比单炎症通道的控制,对新冠肺有更好的治疗效果的?

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2013639, encodeId=f5be201363946, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Wed Mar 30 05:01:38 CST 2022, time=2022-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001358, encodeId=86471001358ba, content=是否全炎症通路的控制,比单炎症通道的控制,对新冠肺有更好的治疗效果的?, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7ced1734358, createdName=1def5843m65(暂无匿称), createdTime=Wed Jul 21 10:54:17 CST 2021, time=2021-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256094, encodeId=06ec125609446, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Wed Jun 23 02:01:38 CST 2021, time=2021-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1338708, encodeId=d66e1338e08d9, content=<a href='/topic/show?id=afff99560c4' target=_blank style='color:#2F92EE;'>#非甾体抗炎药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99560, encryptionId=afff99560c4, topicName=非甾体抗炎药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/7F67E3BE360D6DD1D0A62E3E71E23CB6/100, createdBy=9d8a2500148, createdName=ms8888626721583891, createdTime=Wed Jun 23 02:01:38 CST 2021, time=2021-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1346785, encodeId=dd071346e85d5, content=<a href='/topic/show?id=f20155404fc' target=_blank style='color:#2F92EE;'>#抗炎药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55404, encryptionId=f20155404fc, topicName=抗炎药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Wed Jun 23 02:01:38 CST 2021, time=2021-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=975392, encodeId=ab949e53927b, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=368f5530121, createdName=ms1000000640559067, createdTime=Mon Jun 21 11:18:55 CST 2021, time=2021-06-21, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2013639, encodeId=f5be201363946, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Wed Mar 30 05:01:38 CST 2022, time=2022-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001358, encodeId=86471001358ba, content=是否全炎症通路的控制,比单炎症通道的控制,对新冠肺有更好的治疗效果的?, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7ced1734358, createdName=1def5843m65(暂无匿称), createdTime=Wed Jul 21 10:54:17 CST 2021, time=2021-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256094, encodeId=06ec125609446, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Wed Jun 23 02:01:38 CST 2021, time=2021-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1338708, encodeId=d66e1338e08d9, content=<a href='/topic/show?id=afff99560c4' target=_blank style='color:#2F92EE;'>#非甾体抗炎药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99560, encryptionId=afff99560c4, topicName=非甾体抗炎药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/7F67E3BE360D6DD1D0A62E3E71E23CB6/100, createdBy=9d8a2500148, createdName=ms8888626721583891, createdTime=Wed Jun 23 02:01:38 CST 2021, time=2021-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1346785, encodeId=dd071346e85d5, content=<a href='/topic/show?id=f20155404fc' target=_blank style='color:#2F92EE;'>#抗炎药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55404, encryptionId=f20155404fc, topicName=抗炎药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Wed Jun 23 02:01:38 CST 2021, time=2021-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=975392, encodeId=ab949e53927b, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=368f5530121, createdName=ms1000000640559067, createdTime=Mon Jun 21 11:18:55 CST 2021, time=2021-06-21, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2013639, encodeId=f5be201363946, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Wed Mar 30 05:01:38 CST 2022, time=2022-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001358, encodeId=86471001358ba, content=是否全炎症通路的控制,比单炎症通道的控制,对新冠肺有更好的治疗效果的?, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7ced1734358, createdName=1def5843m65(暂无匿称), createdTime=Wed Jul 21 10:54:17 CST 2021, time=2021-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256094, encodeId=06ec125609446, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Wed Jun 23 02:01:38 CST 2021, time=2021-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1338708, encodeId=d66e1338e08d9, content=<a href='/topic/show?id=afff99560c4' target=_blank style='color:#2F92EE;'>#非甾体抗炎药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99560, encryptionId=afff99560c4, topicName=非甾体抗炎药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/7F67E3BE360D6DD1D0A62E3E71E23CB6/100, createdBy=9d8a2500148, createdName=ms8888626721583891, createdTime=Wed Jun 23 02:01:38 CST 2021, time=2021-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1346785, encodeId=dd071346e85d5, content=<a href='/topic/show?id=f20155404fc' target=_blank style='color:#2F92EE;'>#抗炎药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55404, encryptionId=f20155404fc, topicName=抗炎药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Wed Jun 23 02:01:38 CST 2021, time=2021-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=975392, encodeId=ab949e53927b, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=368f5530121, createdName=ms1000000640559067, createdTime=Mon Jun 21 11:18:55 CST 2021, time=2021-06-21, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2013639, encodeId=f5be201363946, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Wed Mar 30 05:01:38 CST 2022, time=2022-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001358, encodeId=86471001358ba, content=是否全炎症通路的控制,比单炎症通道的控制,对新冠肺有更好的治疗效果的?, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7ced1734358, createdName=1def5843m65(暂无匿称), createdTime=Wed Jul 21 10:54:17 CST 2021, time=2021-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256094, encodeId=06ec125609446, content=<a href='/topic/show?id=587f6339050' target=_blank style='color:#2F92EE;'>#死亡风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63390, encryptionId=587f6339050, topicName=死亡风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Wed Jun 23 02:01:38 CST 2021, time=2021-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1338708, encodeId=d66e1338e08d9, content=<a href='/topic/show?id=afff99560c4' target=_blank style='color:#2F92EE;'>#非甾体抗炎药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99560, encryptionId=afff99560c4, topicName=非甾体抗炎药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/7F67E3BE360D6DD1D0A62E3E71E23CB6/100, createdBy=9d8a2500148, createdName=ms8888626721583891, createdTime=Wed Jun 23 02:01:38 CST 2021, time=2021-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1346785, encodeId=dd071346e85d5, content=<a href='/topic/show?id=f20155404fc' target=_blank style='color:#2F92EE;'>#抗炎药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55404, encryptionId=f20155404fc, topicName=抗炎药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Wed Jun 23 02:01:38 CST 2021, time=2021-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=975392, encodeId=ab949e53927b, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=368f5530121, createdName=ms1000000640559067, createdTime=Mon Jun 21 11:18:55 CST 2021, time=2021-06-21, status=1, ipAttribution=)]
    2021-06-21 ms1000000640559067

    学习学习

    0

相关资讯

BMJ:covid-19大流行期间丹麦非covid疾病住院率下降、死亡率增高

国家封锁期间所有主要非covid-19疾病组的住院人数均有所下降。总体死亡率和因呼吸系统疾病、癌症、肺炎和脓毒症入院的患者死亡率更高。有必要加强对非covid-19严重疾病的管理的关注

BMC Gastroenterology:医疗单位年度肝移植手术量与患者术后死亡率的关系

肝移植 (LT) 是一项重大而、困难的手术,需要涉及多个医疗团队进行相互配合。活体肝移植与移植后手术并发症较高,住院死亡率介于3.6至18.9%之间。

Crit Care:呼吸机相关性肺炎与COVID-19患者死亡率之间的关系

VAP与SARS-CoV-2患者的28天死亡率增加显著相关。但是,与流感性肺炎患者或无病毒感染患者相比,SARS-CoV-2肺炎并未显著改变VAP与28天死亡率之间的关系。

Brit J Cancer:青少年动物产品摄入量与前列腺癌风险和死亡率之间的关系

该研究的结果证据表明,青少年期未加工牛肉摄入量,或可能为牛肉摄入量,与前列腺癌风险和死亡率降低相关。需要进一步研究早期暴露信息,以更好地了解这种关联。

病死率和死亡率如此之高,胃癌早筛切勿掉以轻心!

以胃癌为例,据国家癌症中心的数据,中国2018年新发病例45.6万例、死亡病例39.0万例,约占全球的44.1%和49.9%,其发病率、死亡率分别位居恶性肿瘤第2、第3位。胃癌是我国最常见的消化道肿瘤

JCEM:糖尿病前期患者血清25-羟基维生素D浓度与死亡率之间的关系

在糖尿病前期患者中,较高的血清25(OH)D浓度与较低的全因和心血管疾病死亡率相关。